2026 Q2 - tulosraportti
73 päivää sitten
‧48 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 8 | - | - | ||
| 33 | - | - | ||
| 88 | - | - | ||
| 18 | - | - | ||
| 36 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 28.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 29.7. | ||
2026 Q1 - tulosraportti 7.5. | ||
2025 Q4 - tulosraportti 18.2. | ||
2025 Q3 - tulosraportti 29.10.2025 | ||
2025 Q2 - tulosraportti 30.7.2025 |
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·13 t sittenLau Svenssen suggests a value of 120-150 kroner, but believes shareholders should demand more in the event of a takeover. https://svenssentudborg.dk/photocure-en-lille-aktie-med-store-ambitioner/ Photocure: A small stock with big ambitions Lau Svenssen October 8, 2026 In the video here, Svenssen gives his assessment of Photocure, which operates in a niche market, has international growth opportunities and is a potential takeover candidate. Photocure is a smaller company in the portfolio, but according to Svenssen's assessment, one of the more interesting ones. The company works with light-based diagnostics of bladder cancer and also has a development project within the treatment of cervical cancer. The long-term investment case is mainly about expanding the existing business internationally and gaining greater traction in the US market. The US is central to growth Photocure already has a good position in Europe, but US sales are, according to the analysis, only about half as large as the European ones. This stands in contrast to the general ratio in the pharmaceutical industry, where the US normally constitutes a larger market than Europe. A larger US business is therefore a central part of the company's growth opportunities. In the longer term, Asia, South America and other markets can also contribute as health systems develop. Photocure is at the same time a company that invests in its own development. Earnings are therefore normally only slightly above zero, even though the company is not fundamentally a loss-making business. Challenges with devices and deliveries A significant challenge has been the sales of the devices necessary to use the company's technology. Coatings and deliveries... China and Asieris can become decisive In my assessment, the most interesting part of the investment case is the cooperation with the Chinese partner Asieris. Asieris has completed a development project within a light-based treatment of cervical cancer. According to the analysis, the project was approved in China in March, which was supposed to trigger a milestone payment to Photocure. The payment has, however, become a point of contention. Photocure has not received the amount that the company, in my opinion, believes it is entitled to. This creates uncertainty about both the financial outcome of the cooperation and the further relationship between the two companies. A possible international potential If the treatment can be brought further to other markets, it can open up a significant new earnings opportunity. According to Svenssen, a step has also been taken towards the US market, where Asieris has obtained FDA approval to conduct a phase 3 study. However, it is important to distinguish between permission to conduct a clinical study and final approval for marketing. There are still development and commercial uncertainties. Can Photocure be acquired? The conflict with Asieris gives rise to considering whether Photocure can become an acquisition candidate. My interpretation is therefore that Asieris might be trying to pressure Photocure in order to be able to take over the entire business at a low price. That interpretation is at my own expense. This makes Photocure a possible acquisition candidate. The company finds itself in an unusual situation. I imagine that we can get between 120 and 150 NOK for the share. We ought to get much more if Asieris (or whoever might be behind it) tries to take over everything at a low price. Svenssen thus sees a possible price potential and has himself invested in Photocure. However, it is an investment where the time horizon can be long and where the outcome depends on several uncertain conditions: international growth, device deliveries, the agreement with Asieris and the development of the treatment in new markets. The potential must be seen in the context of the significant risks.
·18 t sittenLau Svenssen wrote an equity review yesterday with many interesting observations regarding Photocure. The article can be read on Svenssen & Tudborg.
2 päivää sitten
Good that the foundation is being quietly strengthened, so everything is ready for Photocure - eventually- ·3 päivää sittenPhotocure looks interesting at today's price around 48,50 kr. The latest price targets are at 75–85 kr, with an average of approx. 80 kr. That means over 60 % upside to the average. It is also positive that insiders have bought shares for approx. 2,35 mill. kr around 48,50–48,70 kr, thus roughly at today's level. The company is growing, making money and guiding for further growth. The lowest price target is 75 kr. It looks like a good risk/reward at today's level.
Nice collection of price targets, at least. Rare that "specialists" are so in agreement. 
·29.9.As soon as there is a bit of turnover we rise, so that is good! 👌 Let's hope there are some positive news or the insiders buying more 😊
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
73 päivää sitten
‧48 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·13 t sittenLau Svenssen suggests a value of 120-150 kroner, but believes shareholders should demand more in the event of a takeover. https://svenssentudborg.dk/photocure-en-lille-aktie-med-store-ambitioner/ Photocure: A small stock with big ambitions Lau Svenssen October 8, 2026 In the video here, Svenssen gives his assessment of Photocure, which operates in a niche market, has international growth opportunities and is a potential takeover candidate. Photocure is a smaller company in the portfolio, but according to Svenssen's assessment, one of the more interesting ones. The company works with light-based diagnostics of bladder cancer and also has a development project within the treatment of cervical cancer. The long-term investment case is mainly about expanding the existing business internationally and gaining greater traction in the US market. The US is central to growth Photocure already has a good position in Europe, but US sales are, according to the analysis, only about half as large as the European ones. This stands in contrast to the general ratio in the pharmaceutical industry, where the US normally constitutes a larger market than Europe. A larger US business is therefore a central part of the company's growth opportunities. In the longer term, Asia, South America and other markets can also contribute as health systems develop. Photocure is at the same time a company that invests in its own development. Earnings are therefore normally only slightly above zero, even though the company is not fundamentally a loss-making business. Challenges with devices and deliveries A significant challenge has been the sales of the devices necessary to use the company's technology. Coatings and deliveries... China and Asieris can become decisive In my assessment, the most interesting part of the investment case is the cooperation with the Chinese partner Asieris. Asieris has completed a development project within a light-based treatment of cervical cancer. According to the analysis, the project was approved in China in March, which was supposed to trigger a milestone payment to Photocure. The payment has, however, become a point of contention. Photocure has not received the amount that the company, in my opinion, believes it is entitled to. This creates uncertainty about both the financial outcome of the cooperation and the further relationship between the two companies. A possible international potential If the treatment can be brought further to other markets, it can open up a significant new earnings opportunity. According to Svenssen, a step has also been taken towards the US market, where Asieris has obtained FDA approval to conduct a phase 3 study. However, it is important to distinguish between permission to conduct a clinical study and final approval for marketing. There are still development and commercial uncertainties. Can Photocure be acquired? The conflict with Asieris gives rise to considering whether Photocure can become an acquisition candidate. My interpretation is therefore that Asieris might be trying to pressure Photocure in order to be able to take over the entire business at a low price. That interpretation is at my own expense. This makes Photocure a possible acquisition candidate. The company finds itself in an unusual situation. I imagine that we can get between 120 and 150 NOK for the share. We ought to get much more if Asieris (or whoever might be behind it) tries to take over everything at a low price. Svenssen thus sees a possible price potential and has himself invested in Photocure. However, it is an investment where the time horizon can be long and where the outcome depends on several uncertain conditions: international growth, device deliveries, the agreement with Asieris and the development of the treatment in new markets. The potential must be seen in the context of the significant risks.
- ·18 t sittenLau Svenssen wrote an equity review yesterday with many interesting observations regarding Photocure. The article can be read on Svenssen & Tudborg.
- 2 päivää sittenGood that the foundation is being quietly strengthened, so everything is ready for Photocure - eventually
- ·3 päivää sittenPhotocure looks interesting at today's price around 48,50 kr. The latest price targets are at 75–85 kr, with an average of approx. 80 kr. That means over 60 % upside to the average. It is also positive that insiders have bought shares for approx. 2,35 mill. kr around 48,50–48,70 kr, thus roughly at today's level. The company is growing, making money and guiding for further growth. The lowest price target is 75 kr. It looks like a good risk/reward at today's level.Nice collection of price targets, at least. Rare that "specialists" are so in agreement.
- ·29.9.As soon as there is a bit of turnover we rise, so that is good! 👌 Let's hope there are some positive news or the insiders buying more 😊
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 8 | - | - | ||
| 33 | - | - | ||
| 88 | - | - | ||
| 18 | - | - | ||
| 36 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 28.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 29.7. | ||
2026 Q1 - tulosraportti 7.5. | ||
2025 Q4 - tulosraportti 18.2. | ||
2025 Q3 - tulosraportti 29.10.2025 | ||
2025 Q2 - tulosraportti 30.7.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
73 päivää sitten
‧48 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 28.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 29.7. | ||
2026 Q1 - tulosraportti 7.5. | ||
2025 Q4 - tulosraportti 18.2. | ||
2025 Q3 - tulosraportti 29.10.2025 | ||
2025 Q2 - tulosraportti 30.7.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·13 t sittenLau Svenssen suggests a value of 120-150 kroner, but believes shareholders should demand more in the event of a takeover. https://svenssentudborg.dk/photocure-en-lille-aktie-med-store-ambitioner/ Photocure: A small stock with big ambitions Lau Svenssen October 8, 2026 In the video here, Svenssen gives his assessment of Photocure, which operates in a niche market, has international growth opportunities and is a potential takeover candidate. Photocure is a smaller company in the portfolio, but according to Svenssen's assessment, one of the more interesting ones. The company works with light-based diagnostics of bladder cancer and also has a development project within the treatment of cervical cancer. The long-term investment case is mainly about expanding the existing business internationally and gaining greater traction in the US market. The US is central to growth Photocure already has a good position in Europe, but US sales are, according to the analysis, only about half as large as the European ones. This stands in contrast to the general ratio in the pharmaceutical industry, where the US normally constitutes a larger market than Europe. A larger US business is therefore a central part of the company's growth opportunities. In the longer term, Asia, South America and other markets can also contribute as health systems develop. Photocure is at the same time a company that invests in its own development. Earnings are therefore normally only slightly above zero, even though the company is not fundamentally a loss-making business. Challenges with devices and deliveries A significant challenge has been the sales of the devices necessary to use the company's technology. Coatings and deliveries... China and Asieris can become decisive In my assessment, the most interesting part of the investment case is the cooperation with the Chinese partner Asieris. Asieris has completed a development project within a light-based treatment of cervical cancer. According to the analysis, the project was approved in China in March, which was supposed to trigger a milestone payment to Photocure. The payment has, however, become a point of contention. Photocure has not received the amount that the company, in my opinion, believes it is entitled to. This creates uncertainty about both the financial outcome of the cooperation and the further relationship between the two companies. A possible international potential If the treatment can be brought further to other markets, it can open up a significant new earnings opportunity. According to Svenssen, a step has also been taken towards the US market, where Asieris has obtained FDA approval to conduct a phase 3 study. However, it is important to distinguish between permission to conduct a clinical study and final approval for marketing. There are still development and commercial uncertainties. Can Photocure be acquired? The conflict with Asieris gives rise to considering whether Photocure can become an acquisition candidate. My interpretation is therefore that Asieris might be trying to pressure Photocure in order to be able to take over the entire business at a low price. That interpretation is at my own expense. This makes Photocure a possible acquisition candidate. The company finds itself in an unusual situation. I imagine that we can get between 120 and 150 NOK for the share. We ought to get much more if Asieris (or whoever might be behind it) tries to take over everything at a low price. Svenssen thus sees a possible price potential and has himself invested in Photocure. However, it is an investment where the time horizon can be long and where the outcome depends on several uncertain conditions: international growth, device deliveries, the agreement with Asieris and the development of the treatment in new markets. The potential must be seen in the context of the significant risks.
- ·18 t sittenLau Svenssen wrote an equity review yesterday with many interesting observations regarding Photocure. The article can be read on Svenssen & Tudborg.
- 2 päivää sittenGood that the foundation is being quietly strengthened, so everything is ready for Photocure - eventually
- ·3 päivää sittenPhotocure looks interesting at today's price around 48,50 kr. The latest price targets are at 75–85 kr, with an average of approx. 80 kr. That means over 60 % upside to the average. It is also positive that insiders have bought shares for approx. 2,35 mill. kr around 48,50–48,70 kr, thus roughly at today's level. The company is growing, making money and guiding for further growth. The lowest price target is 75 kr. It looks like a good risk/reward at today's level.Nice collection of price targets, at least. Rare that "specialists" are so in agreement.
- ·29.9.As soon as there is a bit of turnover we rise, so that is good! 👌 Let's hope there are some positive news or the insiders buying more 😊
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 8 | - | - | ||
| 33 | - | - | ||
| 88 | - | - | ||
| 18 | - | - | ||
| 36 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt